Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 8
2019 5
2020 10
2021 9
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Fluoropyrimidine-induced cardiotoxicity.
Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, Leone F. Depetris I, et al. Crit Rev Oncol Hematol. 2018 Apr;124:1-10. doi: 10.1016/j.critrevonc.2018.02.002. Epub 2018 Feb 7. Crit Rev Oncol Hematol. 2018. PMID: 29548480 Review.
This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive fa …
This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endoth …
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, van Schaik RHN, Mathijssen RHJ, Largiadèr CR; ‘The Working Group on the Implementation of DPD-deficiency Testing in Europe’. de With M, et al. ESMO Open. 2023 Apr;8(2):101197. doi: 10.1016/j.esmoop.2023.101197. Epub 2023 Mar 28. ESMO Open. 2023. PMID: 36989883 Free PMC article.
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC, Pallet N, Boige V, Ciccolini J, Chouchana L, Barin-Le Guellec C, Zaanan A, Narjoz C, Taieb J, Thomas F, Loriot MA; Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER. Etienne-Grimaldi MC, et al. Eur J Cancer. 2023 Mar;181:3-17. doi: 10.1016/j.ejca.2022.11.028. Epub 2022 Dec 9. Eur J Cancer. 2023. PMID: 36621118 Review.
How I treat stage II colon cancer patients.
Taieb J, Karoui M, Basile D. Taieb J, et al. ESMO Open. 2021 Aug;6(4):100184. doi: 10.1016/j.esmoop.2021.100184. Epub 2021 Jul 5. ESMO Open. 2021. PMID: 34237612 Free PMC article. Review.
Then, as fluoropyrimidines (FPs) are the corner stone of CC adjuvant treatment, screening for dihydropyrimidine dehydrogenase deficiency is mandatory in western countries. ...
Then, as fluoropyrimidines (FPs) are the corner stone of CC adjuvant treatment, screening for dihydropyrimidine dehydrogenase …
Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine.
Perrain V, Bihan K, Bompaire F, Houillier C, Jomier F, Leclercq D, Combret S, Mahé J, Ricard D, Berzero G, Psimaras D. Perrain V, et al. Eur J Neurol. 2021 Jul;28(7):2396-2402. doi: 10.1111/ene.14857. Epub 2021 Apr 19. Eur J Neurol. 2021. PMID: 33817933 Review.
Resuming the agent responsible for toxicity might be feasible in selected cases, after having excluded dihydropyrimidine dehydrogenase deficiency, if expected benefits outweigh the risks....
Resuming the agent responsible for toxicity might be feasible in selected cases, after having excluded dihydropyrimidine dehydroge …
44 results